Spinraza denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Spinraza

Prior authorization (PA) for Spinraza (nusinersen) is standard across most commercial insurers, including Aetna. A "prior-auth-required" denial means the drug was dispensed or administered without an approved PA on file, or that a PA request was submitted but denied because the submitted information did not meet Aetna's coverage criteria.

If the denial is due to a missing PA: submit the PA immediately, as most plans allow retroactive authorization requests within a defined window after the service date. If the PA was submitted and denied on clinical grounds, the full appeal process below applies.

## Federal Appeal Rights

• Internal appeal: You are entitled to a full internal appeal of a PA denial. Request the specific clinical criteria Aetna applied in writing — this is your starting point for building the appeal.
• ACA §2719 external review: After exhausting internal appeals, external review by a certified IRO is available for non-grandfathered plans. The window is typically approximately four months from the final internal denial.
• ERISA §503: Employer-plan members have full-and-fair review rights, including access to all evidence and criteria used.
• Expedited review: For an ongoing or urgent treatment need in a patient with SMA — a condition where treatment gaps can cause irreversible harm — request expedited PA review and expedited appeal simultaneously.

## Documentation to Gather for the PA Appeal

• Diagnosis documentation: Genetic testing confirming SMA diagnosis and SMN1/SMN2 status; neuromuscular specialist diagnosis notes.
• Functional status: Documented motor function assessments, respiratory status, and nutritional status from the chart.
• Clinical course: Sequential notes showing disease trajectory and the medical rationale for initiating or continuing Spinraza.
• Prescriber attestation: Confirmation from the treating specialist that the treatment meets the criteria in Aetna's Clinical Policy Bulletin for Spinraza — specifically addressing each criterion listed.
• FDA prescribing information: Attach to confirm the on-label use.
• Any prior PA approvals: If Spinraza was previously authorized by Aetna for this patient, include prior approval letters as evidence of established coverage.

## Criteria-Mapping Framework

Obtain Aetna's Clinical Policy Bulletin for Spinraza before submitting the appeal. Then build a structured response:

| Aetna PA Criterion | Documentation Provided | |---|---| | Confirmed SMA diagnosis with genetic testing | Genetic report, [lab], [date] | | Specialist prescriber (neuromuscular/neurology) | Prescriber NPI + specialty on file | | Functional status documented at initiation | Motor assessment note, [date] | | [Other stated criterion] | [Specific chart citation] |

For retroactive PA requests, include a brief narrative explaining why the PA was not obtained in advance — urgent clinical circumstances, administrative error, emergency initiation — as this context matters to reviewers.